



### Flublok® Quadrivalent (influenza vaccine) – New Formulation Approval

- On October 7, 2016, the [FDA approved Protein Sciences Corporation's Flublok Quadrivalent \(influenza vaccine\)](#), for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for use in persons 18 years of age and older.
- Flublok Quadrivalent protects against 4 strains of influenza, 3 of the same strains found in trivalent [Flublok®](#) plus an additional B strain. Flublok Quadrivalent contains three times more active ingredient than all other quadrivalent vaccines (eg, [Afluria® Quadrivalent](#), [Fluarix® Quadrivalent](#), [Flucelvax® Quadrivalent](#), [Flulaval® Quadrivalent](#), and [Fluzone® Quadrivalent](#)).
  - Refer to the individual drug labels for the FDA-approved age ranges.
- The relative efficacy of Flublok Quadrivalent was demonstrated in a clinical study of 8,963 adults (≥ 50 years old). Subjects who received Flublok Quadrivalent were over 40% less likely to get cell-culture confirmed influenza than those that received a leading egg-produced quadrivalent flu vaccine.
  - In addition, the efficacy of Flublok is relevant to Flublok Quadrivalent because both vaccines are manufactured using the same process and have overlapping compositions. The efficacy of Flublok (trivalent formulation) in protecting against influenza illness was evaluated in a placebo-controlled, multicenter trial conducted in the U.S. during the 2007 – 2008 influenza season in adults 18-49 years of age.
- Warnings and precautions with Flublok Quadrivalent include managing allergic reactions, Guillain Barré Syndrome, altered immunocompetence, and limitations of vaccine effectiveness.
- In adults 18 through 49 years of age, the most common adverse reactions (≥ 10%) with Flublok Quadrivalent use were tenderness and pain at the injection site, headache, fatigue, myalgia, and arthralgia.
- In adults 50 years of age and older, the most common adverse reactions (≥ 10%) with Flublok Quadrivalent use were tenderness and pain at the injection site, headache, and fatigue.
- Flublok is administered as a single intramuscular 0.5 mL dose.
- Protein Sciences Corporation plans to launch Flublok Quadrivalent as 0.5 mL single dose pre-filled syringes in 2017.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

Rx News® is published by the OptumRx Clinical Services Department.

©2016 Optum, Inc. All rights reserved.